Ironwood Pharmaceuticals Pre-Tax Income 2010-2024 | IRWD

Ironwood Pharmaceuticals pre-tax income from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
Ironwood Pharmaceuticals Annual Pre-Tax Income
(Millions of US $)
2024 $65
2023 $-948
2022 $252
2021 $201
2020 $109
2019 $59
2018 $-194
2017 $-55
2016 $-82
2015 $-143
2014 $-190
2013 $-273
2012 $-73
2011 $-65
2010 $-59
2009 $-60
Ironwood Pharmaceuticals Quarterly Pre-Tax Income
(Millions of US $)
2024-12-31 $24
2024-09-30 $17
2024-06-30 $19
2024-03-31 $5
2023-12-31 $30
2023-09-30 $32
2023-06-30 $-1,076
2023-03-31 $66
2022-12-31 $72
2022-09-30 $70
2022-06-30 $54
2022-03-31 $56
2021-12-31 $46
2021-09-30 $60
2021-06-30 $54
2021-03-31 $40
2020-12-31 $45
2020-09-30 $36
2020-06-30 $25
2020-03-31 $3
2019-12-31 $48
2019-09-30 $21
2019-06-30 $12
2019-03-31 $-22
2018-12-31 $25
2018-09-30 $-152
2018-06-30 $-24
2018-03-31 $-43
2017-12-31 $74
2017-09-30 $-32
2017-06-30 $-44
2017-03-31 $-53
2016-12-31 $-14
2016-09-30 $-33
2016-06-30 $-22
2016-03-31 $-13
2015-12-31 $-14
2015-09-30 $-47
2015-06-30 $-48
2015-03-31 $-33
2014-12-31 $-38
2014-09-30 $-42
2014-06-30 $-60
2014-03-31 $-50
2013-12-31 $-52
2013-09-30 $-62
2013-06-30 $-65
2013-03-31 $-94
2012-12-31 $-44
2012-09-30 $48
2012-06-30 $-41
2012-03-31 $-36
2011-12-31 $-7
2011-09-30 $-21
2011-06-30 $-19
2011-03-31 $-18
2010-12-31 $-12
2010-09-30 $-16
2010-06-30 $-17
2010-03-31 $-14
2009-12-31 $-15
2009-09-30 $-8
2009-06-30 $-19
2009-03-31 $-18
Sector Industry Market Cap Revenue
Medical MED-DRUGS $0.148B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) JP $95.374B 35.78
Zoetis (ZTS) US $69.448B 26.29
Daiichi Sankyo, - (DSNKY) JP $48.414B 24.63
Takeda Pharmaceutical (TAK) JP $47.824B 10.59
Sandoz Group AG (SDZNY) CH $18.977B 0.00
Summit Therapeutics (SMMT) US $18.321B 0.00
Merck (MKKGY) DE $17.848B 14.77
Shionogi (SGIOY) JP $14.096B 14.12
United Therapeutics (UTHR) US $13.255B 11.73
Neurocrine Biosciences (NBIX) US $10.546B 32.40
IPSEN (IPSEY) FR $9.907B 0.00
Orion OYJ (ORINY) FI $9.027B 24.41
Corcept Therapeutics (CORT) US $7.580B 57.65
Madrigal Pharmaceuticals (MDGL) US $7.276B 0.00
Stevanato Group S.p.A (STVN) IT $6.281B 39.88
Ono Pharmaceutical (OPHLF) JP $5.988B 12.26
Hikma Pharmaceuticals Plc (HKMPF) GB $5.813B 0.00
Ionis Pharmaceuticals (IONS) US $5.047B 0.00
Grifols, S.A (GRFS) ES $4.827B 0.00
Soleno Therapeutics (SLNO) US $3.744B 0.00
Crinetics Pharmaceuticals (CRNX) US $3.138B 0.00
Catalyst Pharmaceuticals (CPRX) US $2.960B 12.02
AMNEAL PHARMACEUTICALS, INC (AMRX) US $2.399B 14.89
Hypermarcas (HYPMY) BR $2.350B 15.46
Recursion Pharmaceuticals (RXRX) US $2.211B 0.00
NewAmsterdam Pharma (NAMS) NL $2.200B 0.00
BioCryst Pharmaceuticals (BCRX) US $1.822B 0.00
Centessa Pharmaceuticals (CNTA) GB $1.798B 0.00
Indivior (INDV) US $1.593B 6.75
Guardian Pharmacy Services (GRDN) US $1.568B 0.00
Evotec AG (EVO) DE $1.502B 0.00
ARS Pharmaceuticals (SPRY) US $1.391B 177.00
Dyne Therapeutics (DYN) US $1.362B 0.00
Ocular Therapeutix (OCUL) US $1.359B 0.00
Ardelyx (ARDX) US $1.304B 0.00
Aurinia Pharmaceuticals Inc (AUPH) CA $1.121B 45.56
Enliven Therapeutics (ELVN) US $0.974B 0.00
Harrow (HROW) US $0.917B 0.00
Collegium Pharmaceutical (COLL) US $0.869B 4.62
Avadel Pharmaceuticals (AVDL) IE $0.832B 0.00
Xencor (XNCR) US $0.773B 0.00
Cronos Group (CRON) CA $0.721B 0.00
AleAnna (ANNA) US $0.718B 0.00
Xeris Biopharma Holdings (XERS) US $0.701B 0.00
KalVista Pharmaceuticals (KALV) US $0.676B 0.00
Organogenesis (ORGO) US $0.629B 0.00
Akebia Therapeutics (AKBA) US $0.626B 0.00
Bioventus (BVS) US $0.595B 15.45
Savara (SVRA) US $0.563B 0.00
Relay Therapeutics (RLAY) US $0.561B 0.00
USANA Health Sciences (USNA) US $0.529B 11.35
Regulus Therapeutics (RGLS) US $0.520B 0.00
Theravance Biopharma (TBPH) KY $0.520B 0.00
Verve Therapeutics (VERV) US $0.490B 0.00
Tourmaline Bio (TRML) US $0.458B 0.00
Amylyx Pharmaceuticals (AMLX) US $0.458B 0.00
Elite Pharmaceuticals (ELTP) US $0.454B 0.00
Zevra Therapeutics (ZVRA) US $0.418B 0.00
Altimmune (ALT) US $0.398B 0.00
Siga Technologies (SIGA) US $0.388B 6.62
Oruka Therapeutics (ORKA) US $0.378B 0.00
CytoDyn (CYDY) US $0.368B 0.00
Heron Therapeutics (HRTX) US $0.358B 0.00
Rigel Pharmaceuticals (RIGL) US $0.334B 19.92
Aquestive Therapeutics (AQST) US $0.298B 0.00
ProKidney (PROK) US $0.250B 0.00
Avita Medical (RCEL) US $0.247B 0.00
Nature's Sunshine Products (NATR) US $0.227B 26.70
Wellgistics Health (WGRX) US $0.223B 0.00
OmniAb (OABI) US $0.216B 0.00
Esperion Therapeutics (ESPR) US $0.195B 24.60
MediWound (MDWD) IL $0.186B 0.00
Larimar Therapeutics (LRMR) US $0.183B 0.00
Korro Bio (KRRO) US $0.173B 0.00
Inhibikase Therapeutics (IKT) US $0.167B 0.00
Aldeyra Therapeutics (ALDX) US $0.162B 0.00
4D Molecular Therapeutics (FDMT) US $0.159B 0.00
Journey Medical (DERM) US $0.159B 0.00
Lexeo Therapeutics (LXEO) US $0.156B 0.00
Nanobiotix S.A (NBTX) FR $0.156B 0.00
Procaps Group, S.A (PROCF) LU $0.156B 0.00
Aclaris Therapeutics (ACRS) US $0.149B 0.00
Nektar Therapeutics (NKTR) US $0.145B 0.00
Profound Medical (PROF) CA $0.145B 0.00
Lyell Immunopharma (LYEL) US $0.139B 0.00
Protara Therapeutics (TARA) US $0.133B 0.00
Enanta Pharmaceuticals (ENTA) US $0.129B 0.00
Innate Pharma SA (IPHYF) FR $0.122B 0.00
Tonix Pharmaceuticals Holding (TNXP) US $0.116B 0.00
VAXART, INC (VXRT) US $0.098B 0.00
OptiNose (OPTN) US $0.095B 0.00
Cardiol Therapeutics (CRDL) CA $0.093B 0.00
Corbus Pharmaceuticals Holdings (CRBP) US $0.092B 0.00
Champions Oncology (CSBR) US $0.088B 14.50
Achieve Life Sciences (ACHV) CA $0.085B 0.00
Arch Biopartners (ACHFF) CA $0.083B 0.00
Galectin Therapeutics (GALT) US $0.082B 0.00
ESSA Pharma (EPIX) CA $0.079B 0.00
Cassava Sciences (SAVA) US $0.078B 0.00
Unicycive Therapeutics (UNCY) US $0.078B 0.00
Context Therapeutics (CNTX) US $0.077B 0.00
Telomir Pharmaceuticals (TELO) US $0.075B 0.00
Dominari Holdings (DOMH) US $0.075B 0.00
Nutriband (NTRB) US $0.070B 0.00
Pyxis Oncology (PYXS) US $0.068B 0.00
Cumberland Pharmaceuticals (CPIX) US $0.067B 0.00
Inotiv (NOTV) US $0.067B 0.00
Gain Therapeutics (GANX) US $0.064B 0.00
Assertio Holdings (ASRT) US $0.062B 0.00
Fractyl Health (GUTS) US $0.062B 0.00
Vivani Medical (VANI) US $0.062B 0.00
Allergy Therapeutics (AGYTF) GB $0.059B 0.00
Karyopharm Therapeutics (KPTI) US $0.058B 0.00
Metagenomi (MGX) US $0.056B 0.00
ElectroCore (ECOR) US $0.054B 0.00
Avalo Therapeutics (AVTX) US $0.054B 0.00
PMV Pharmaceuticals (PMVP) US $0.052B 0.00
Century Therapeutics (IPSC) US $0.048B 0.00
Mural Oncology (MURA) IE $0.045B 0.00
Verrica Pharmaceuticals (VRCA) US $0.043B 0.00
Acrivon Therapeutics (ACRV) US $0.042B 0.00
Reviva Pharmaceuticals Holdings (RVPH) US $0.041B 0.00
Prelude Therapeutics (PRLD) US $0.040B 0.00
Rafael Holdings (RFL) US $0.040B 0.00
Iterum Therapeutics (ITRM) IE $0.039B 0.00
SCYNEXIS (SCYX) US $0.038B 0.00
NRx Pharmaceuticals (NRXP) US $0.036B 0.00
Surrozen (SRZN) US $0.034B 0.00
FibroGen (FGEN) US $0.034B 0.00
PolyPid (PYPD) IL $0.029B 0.00
Tempest Therapeutics (TPST) US $0.025B 0.00
CASI Pharmaceuticals (CASI) CN $0.024B 0.00
Enlivex Therapeutics (ENLV) IL $0.022B 0.00
Jupiter Neurosciences (JUNS) US $0.021B 0.00
VYNE Therapeutics (VYNE) US $0.020B 0.00
Mannatech (MTEX) US $0.020B 7.86
Lipocine (LPCN) US $0.019B 0.00
Natural Alternatives (NAII) US $0.019B 0.00
DURECT (DRRX) US $0.018B 0.00
GlycoMimetics (GLYC) US $0.017B 0.00
TherapeuticsMD (TXMD) US $0.016B 0.00
Vivos Therapeutics (VVOS) US $0.016B 0.00
BioVie (BIVI) US $0.016B 0.00
MEI Pharma (MEIP) US $0.014B 0.00
ProPhase Labs (PRPH) US $0.014B 0.00
MARKER THERAPEUTICS, INC (MRKR) US $0.013B 0.00
TransCode Therapeutics (RNAZ) US $0.013B 0.00
Cosmos Health (COSM) US $0.013B 0.00
Scienture Holdings (SCNX) US $0.012B 0.00
Minerva Neurosciences (NERV) US $0.012B 8.79
Relmada Therapeutics (RLMD) US $0.012B 0.00
BioLineRx (BLRX) IL $0.011B 0.00
Plus Therapeutics (PSTV) US $0.011B 0.00
Ernexa Therapeutics (ERNA) US $0.010B 0.00
Kiora Pharmaceuticals (KPRX) US $0.010B 3.16
Biomerica (BMRA) US $0.009B 0.00
Addex Therapeutics (ADXN) CH $0.009B 0.00
Phio Pharmaceuticals (PHIO) US $0.009B 0.00
Talphera (TLPH) US $0.009B 0.00
Carisma Therapeutics (CARM) US $0.008B 0.00
Ainos (AIMD) US $0.008B 0.00
XTL Biopharmaceuticals (XTLB) IL $0.008B 0.00
Mangoceuticals (MGRX) US $0.008B 0.00
Nuvilex (PMCB) US $0.008B 0.00
Jaguar Animal Health (JAGX) US $0.008B 0.00
Indaptus Therapeutics (INDP) US $0.008B 0.00
Traws Pharma (TRAW) US $0.008B 0.00
Lyra Therapeutics (LYRA) US $0.007B 0.00
Citius Pharmaceuticals (CTXR) US $0.007B 0.00
Conduit Pharmaceuticals (CDT) US $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) US $0.006B 0.00
NLS Pharmaceutics (NLSP) CH $0.005B 0.00
Klotho Neurosciences (KLTO) US $0.005B 0.00
Aptorum Group (APM) GB $0.005B 0.00
CERo Therapeutics Holdings (CERO) US $0.005B 0.00
Clearmind Medicine (CMND) CA $0.004B 0.00
Xenetic Biosciences (XBIO) US $0.004B 0.00
XORTX Therapeutics (XRTX) CA $0.004B 0.00
Quoin Pharmaceuticals (QNRX) US $0.004B 0.00
Redhill Biopharma (RDHL) IL $0.004B 0.00
InMed Pharmaceuticals (INM) CA $0.004B 0.00
Alaunos Therapeutics (TCRT) US $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) US $0.004B 0.00
SciSparc (SPRC) IL $0.003B 0.00
Qualigen Therapeutics (QLGN) US $0.003B 0.00
Incannex Healthcare (IXHL) AU $0.002B 0.00
Galmed Pharmaceuticals (GLMD) IL $0.002B 0.00
TNF Pharmaceuticals (TNFA) US $0.002B 0.00
PainReform (PRFX) IL $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) US $0.002B 0.00
China SXT Pharmaceuticals (SXTC) CN $0.002B 0.00
SHINECO (SISI) CN $0.002B 0.00
Salarius Pharmaceuticals (SLRX) US $0.001B 0.00
Heatwurx (PCSA) US $0.001B 0.00
Petros Pharmaceuticals (PTPI) US $0.001B 0.00
Universe Pharmaceuticals INC (UPC) CN $0.000B 0.00
Aditxt (ADTX) US $0.000B 0.00
4D Pharma (LBPS) GB $0.000B 0.00
Patheon (PTHN) NL $0.000B 0.00
RVL Pharmaceuticals (RVLP) US $0.000B 0.00
Silence Therapeutics (SLN) GB $0.000B 0.00